|
| |
|
 | |
           
|  |
|  |

|
Biogen Idec Inc. - [Ticker: BIIB] | | | Última Transacción | 131,500 | Hora de Cotización | 2012-05-23 - 21:00 | | Variación | -0,830 (-0.63%) | Rango 52 Semanas | [83,830 - 133,540] | | Máximo | 132,890 | Mínimo | 130,880 | | Volumen | 1.501.777 | Volumen Medio (3m) | 1.196.640 | | Demanda / Oferta | 126,800 x 100 - 135,400 x 100 | Yield | N/A | | Cierre Anterior | 132,330 | PER | 26,00% | | Apertura | 131,970 | EPS | 5,09 | | Fecha Ex-Dividendo | N/A | Fecha Dividendo | N/A | | Capitalización Bursátil | 31 | Objetivo Estimado 1 Año | 141,530 | | Nota: Los datos pueden tener un retraso de algunos minutos. |
| | Ver cotizaciones de otros activos |
| Últimos 10 Tópicos en el Foro relacionados con Biogen Idec Inc.: | | No se han encontrado tópicos relacionados con Biogen Idec Inc. [BIIB], pero se aconseja la búsqueda en el Foro para tópicos relacionados con Biogen Idec Inc.. |
|
Noticias de Biogen Idec Inc. [BIIB]: (ordenadas por relevancia)
|
|
The biggest R&D spenders in biotechFierceBiotechAs Biogen Idec ($BIIB) showed over the past year, unhappy investors will back off on calls to cut research costs if you show some major headway on big new products. Now I'm waiting to see if the new crew in charge of Amgen ($AMGN) will win a grace ...y más » |
|
Data on Elan & Biogen's TysabriZacks.comBiogen Idec (BIIB - Analyst Report) and Elan Corporation, plc (ELN - Snapshot Report) recently announced the publishing of research from the Tysabri risk management program in the New England Journal of Medicine. The research was based on data from ...y más » |
|
Midday Glance: Biotechnology companiesCBS NewsNEW YORK ? Shares of some top biotechnology companies are down at 1 pm: Amgen Inc. fell $.84 or 1.2 percent, to $68.07. Biogen Idec fell $.57 or .4 percent, to $131.76. Celgene Corp. fell $.91 or 1.3 percent, to $68.74. Gilead Sciences Inc. fell $.61 ...y más » |
|
Data on Elan & Biogen's Tysabri - Analyst BlogNASDAQBiogen Idec ( BIIB ) and Elan Corporation, plc ( ELN ) recently announced the publishing of research from the Tysabri risk management program in the New England Journal of Medicine . The research was based on data from Tysabri trials, post-marketing ...y más » |
| Para más noticias de Biogen Idec Inc. hacer clic aquí: Noticias de Biogen Idec Inc. |
|
Anchura de la Página: Imagen de Fondo: |
|  | |
|
|